Table 2 Investigated MGMT methylation and IDH1 mutation among studied groups
From: Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma
Investigated items | Non-neuro-oncological patients | GBM |
|---|---|---|
(n = 20) | (n = 58) | |
MGMT methylation | ||
 < 66% (low methylation) | 0 (0%) | 28 (48.3%) |
 ≥ 66% (highly methylated) | 20 (100%) | 30 (51.7%) |
|  | X2 = 15, P < 0.0001 | |
IDH1 mutation | ||
 Wild type | 20 (100%) | 43 (74.1%) |
 Mutant type | 0 (0%) | 15 (25.9%) |
|  | X2 = 6.4, P = 0.011 | |